I
ImmuneOnco Biopharma
Dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells
About ImmuneOnco Biopharma
ImmuneOnco Biopharma, founded in June 2015 in Zhangjiang High Tech Park of Shanghai, China, is an early-stage biotechnology company focused on developing innovative therapies for cancer and viral infections. The company leverages advanced platforms that utilize two types of innate immune cells to achieve its therapeutic goals.
Read full description
ImmuneOnco operates in the biopharmaceutical market, serving clients such as healthcare providers, research institutions, and pharmaceutical companies. Its business model revolves around the research and development of novel biological medicines, with a particular emphasis on natural killer (NK) cells, which are crucial for the body's defense against diseases. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary therapies.
At a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Huangpu, China
- Listing
- IPO 2023
- Open positions
- 26
- Dealroom signal
- 59.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Oct 2025 | $42M | — | Undisclosed | ↗ |
| IPOOther financing | Sep 2023 | $30M | $30M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $21M | 0% | −$27M | -129.2% |
| 2025 | $21M | +108.1% | −$27M | -129.2% |
| 2024 | $10M | +19109.6% | −$38M | -376.6% |
| 2023 | $53K | -28.3% | −$46M | -85786.8% |
| 2022 | $74K | -89.4% | −$53M | -71466.5% |
| 2021 | $697K | — | −$99M | -14233.3% |
Growth signals
Latest recorded traffic for ImmuneOnco Biopharma is 2K monthly website visits, down 16.7% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- ZIZhangjiang Science and Technology Investment
Series A3 investors entered at this stage
Lapam Capital- LILangsheng Investment
Lilly Asia Ventures
Series B and later7 investors entered at this stage
- GIGreater Bay Area Homeland Investments
- SCSunshine Insurance Group Co
- CTCCB Trust
- GMGuoke Jiahe (Beijing) Investment Management
- FFFounder H Fund
- SMShanghai Milestone Asset Management
Shenzhen CDF Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ImmuneOnco Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ImmuneOnco Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.